4.7 Article

Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a gray zone?

期刊

ALZHEIMERS & DEMENTIA
卷 15, 期 10, 页码 1348-1356

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2019.07.010

关键词

NIA-AA; AT(N); Biomarker thresholds; Perithreshold; Amyloid PET; SUVR; Alzheimer's clinical syndrome; Cognitive decline; Alzheimer's disease Neuroimaging Initiative; ADNI

资金

  1. MRC [MR/L023784/2]
  2. UK Medical Research Council
  3. Department for International Development [MR/R015600/1]
  4. MRC [MR/R015600/1] Funding Source: UKRI

向作者/读者索取更多资源

The 2018 National Institute on Aging and the Alzheimer's Association (NIA-AA) research framework recently redefined Alzheimer's disease (AD) as a biological construct, based on in vivo biomarkers reflecting key neuropathologic features. Combinations of normal/abnormal levels of three biomarker categories, based on single thresholds, form the AD signature profile that defines the biological disease state as a continuum, independent of clinical symptomatology. While single thresholds may be useful in defining the biological signature profile, we provide evidence that their use in studies with cognitive outcomes merits further consideration. Using data from the Alzheimer's Disease Neuroimaging Initiative with a focus on cortical amyloid binding, we discuss the limitations of applying the biological definition of disease status as a tool to define the increased likelihood of the onset of the Alzheimer's clinical syndrome and the effects that this may have on trial study design. We also suggest potential research objectives going forward and what the related data requirements would be. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据